A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

Open for enrollment

(956) 362-2378

Please contact us for more information or to learn if you are eligible to participate.

To determine the effect of once-daily, oral administration of 80 or 100 mg MGL-3196 versus matching placebo on NASH

Principal Investigator	Fernando Membreno, MD
Co-PI	John Rodriguez
Sponsor	Madrigal Pharmaceuticals, Inc.
Type of Trial	Interventional

5323 S. McColl Rd., Edinburg, TX 78539

(956) 362-2390